You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

CLINICAL TRIALS PROFILE FOR CEFTAZIDIME SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ceftazidime sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Baxter Healthcare Corporation Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated GlaxoSmithKline Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Roche Pharma AG Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Vaincre la Mucoviscidose Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT01601093 ↗ Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Suspended Xiangbei Welman Pharmaceutical Co., Ltd Phase 2 2011-11-01 In the proposed study, the investigators plan to evaluate the efficacy and safety of Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ceftazidime sodium

Condition Name

Condition Name for ceftazidime sodium
Intervention Trials
Urinary Tract Infections 1
Atrial Fibrillation 1
Chronic Appendicitis 1
Cystic Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ceftazidime sodium
Intervention Trials
Urinary Tract Infections 1
Cystic Fibrosis 1
Respiratory Tract Infections 1
Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ceftazidime sodium

Trials by Country

Trials by Country for ceftazidime sodium
Location Trials
China 2
France 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ceftazidime sodium

Clinical Trial Phase

Clinical Trial Phase for ceftazidime sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 2 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ceftazidime sodium
Clinical Trial Phase Trials
Enrolling by invitation 1
Not yet recruiting 1
Suspended 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ceftazidime sodium

Sponsor Name

Sponsor Name for ceftazidime sodium
Sponsor Trials
Baxter Healthcare Corporation 1
GlaxoSmithKline 1
Roche Pharma AG 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ceftazidime sodium
Sponsor Trials
Industry 5
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.